Oral Oncology Reports最新文献

{"title":"Swallowing function, body image and uncertainty in illness after reconstruction in oral cancer survivors","authors":"Chen-Chan Kuo ,&nbsp;Shiu-Yu C. Katie Lee ,&nbsp;Chun-Ta Liao","doi":"10.1016/j.oor.2025.100734","DOIUrl":"10.1016/j.oor.2025.100734","url":null,"abstract":"<div><h3>Background</h3><div>Swallowing and body image are the main concerns after reconstruction for oral cancer. Perceiving uncertainty or an unpredictable future is a significant psychosocial stressor in cancer survivors. This study aimed to explore swallowing function, body image, and uncertainty after the reconstruction for oral cancer, and to examine their associations.</div></div><div><h3>Methods</h3><div>A consecutive sample of 155 oral cancer adults (147 males and 8 females), with or without adjuvants, and surviving 3–30 months after primary microvascular free flaps, were included. The main outcomes were assessed by the Body Image Scale, EORTC QLQ-HN 35, and Mishel's Uncertainty in Illness Scale.</div></div><div><h3>Results</h3><div>Participants reported moderate disturbance in appearance, body as a whole, and sexual attraction, and a moderate-to-low level of EORTC swallowing, speech, and social problems. Less than 20 % have pursued cosmetic surgeries after reconstruction. After adjusting for demographic and clinical factors, poor body image (<em>β</em> = .318), poor speech (<em>β</em> = .198), lower household incomes (<em>β</em> = -.153), and farmers v.s. counterparts were more likely to have higher uncertainty in illness (Adj.R² = .347).</div></div><div><h3>Conclusions</h3><div>Along with body image disturbance and swallowing problems, financial burden or work-related stress are significant risk factors for higher uncertainty in illness. Providing supportive care to cope with body image disturbances, swallowing and speech problems, and to improve work or financial status are warranted to help oral cancer survivors to cope with uncertainty in illness after free flaps.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100734"},"PeriodicalIF":0.0,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143851608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Resection of a left carotid body tumor in a young female patient”","authors":"Lucas Alves da Mota Santana ,&nbsp;Lara Góis Floresta ,&nbsp;Rajiv Gandhi Gopalsamy ,&nbsp;Bernardo Ferreira Brasileiro ,&nbsp;Cleverson Luciano Trento ,&nbsp;Lysandro Pinto Borges","doi":"10.1016/j.oor.2025.100733","DOIUrl":"10.1016/j.oor.2025.100733","url":null,"abstract":"","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100733"},"PeriodicalIF":0.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143686694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypofractionated adjuvant radiotherapy in cutaneous squamous cell and basal cell carcinoma of the head and neck: 50(Gy) in 20 study","authors":"Marcus Hu ,&nbsp;Howard Liu ,&nbsp;Anne Bernard ,&nbsp;Michael Efendy ,&nbsp;Sandro V. Porceddu","doi":"10.1016/j.oor.2025.100732","DOIUrl":"10.1016/j.oor.2025.100732","url":null,"abstract":"<div><h3>Purpose</h3><div>To assess clinical outcomes and tolerability of patients with cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) of the head and neck region, treated with adjuvant radiotherapy prescribed to a moderately hypofractionated regimen of 50Gy in 20 fractions.</div></div><div><h3>Methods and materials</h3><div>Eligibility for this retrospective study included patients with cutaneous SCC and BCC of the head and neck who received adjuvant radiotherapy to a dose of 50Gy in 20 fractions (2.5Gy per fraction) between 1/1/2007 and 31/12/2019 at a tertiary Queensland hospital. Primary endpoint was freedom from local failure (FFLF). Secondary outcomes were loco-regional recurrence-free survival (LRRFS), overall survival (OS) and toxicity rates. Acute toxicities were retrospectively collected and reported according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0.</div></div><div><h3>Results</h3><div>A total of 126 patients were evaluated in this study with a median follow up period of 19.7 months (interquartile range 1.63–121.03). The median age was 68.3 years old. Twenty-six patients were immunosuppressed. Predominant histopathology was SCC (63.5 %). The majority were staged pT1-2 (74.6 %), and clinically or pathologically N0 (96.8 %). 122 patients received adjuvant radiotherapy to the primary tumour bed, and four patients received treatment both the primary and nodal region. FFLF was 95.8 % and 92.2 % at 2 and 5 years, respectively. No statistically significant clinico-pathological factors were prognostic of FFLF. LRRFS was 90.5 % at 2 years and 83.1 % at 5 years. OS was 88.7 % at 2 years and 69.9 % at 5 years. Five of the 21 deaths were related to the index cutaneous carcinoma. Grade 3 radiation dermatitis and mucositis occurred in 13.5 % and 4.0 % of patients, respectively. There were no grade 4/5 toxicities. Four patients required treatment breaks, of which two were planned breaks. No patient required enteral feeding during their RT course.</div></div><div><h3>Conclusion</h3><div>This is the largest series to date evaluating a single moderately hypofractionated adjuvant radiotherapy regimen for cutaneous SCC and BCC of the head and neck. This regimen was associated with high locoregional control and was well tolerated. A moderately hypofractionated course of adjuvant radiotherapy in cutaneous SCC and BCC can be a suitable option to reduce treatment duration.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100732"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143576889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral potentially malignant disorders: Challenges for patient participation due to opacity","authors":"Brenda Bogaert","doi":"10.1016/j.oor.2025.100731","DOIUrl":"10.1016/j.oor.2025.100731","url":null,"abstract":"<div><div>Opacity – or the lack of transparency - impacts patients' ability to participate in and contribute to decision-making. This contribution examines how opacity affects patient engagement in the context of oral potentially malignant disorders. The discussion focuses on three key areas: the effects of unclear disease classifications on patient perceptions of their health; the ways in which ambiguous healthcare pathways create barriers for both patients and providers; and the broader impact of opacity on patient autonomy. The conclusion explores strategies to reduce or mitigate these challenges, including fostering epistemic networks for patients and healthcare providers and embracing the value of humility in care work.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100731"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143592377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dysregulation of glucose-6-phosphate dehydrogenase in head and neck squamous cell carcinoma: Pathways, mutations, and therapeutic opportunities","authors":"Santhakumar Egambaram ,&nbsp;Mohamed Rizwan Ghouse ,&nbsp;Anishkiran Balasundar,&nbsp;Rajesh Parsanathan","doi":"10.1016/j.oor.2025.100726","DOIUrl":"10.1016/j.oor.2025.100726","url":null,"abstract":"<div><h3>Objective</h3><div>Glucose-6-phosphate dehydrogenase <strong>(</strong>G6PD) deficiency, the most common human enzyme defect, confers malaria resistance and is linked to reduced cancer risk. Its upregulation in malignancies suggests a critical role in tumour progression. This study examines G6PD in head and neck squamous cell carcinoma (HNSCC), focusing on its expression, genetic alterations, interactions, and therapeutic potential.</div></div><div><h3>Materials and methods</h3><div>Bioinformatics tools, including UALCAN, Human Protein Atlas, GEPIA2, cBioPortal, muTarget, GeneMANIA, Cancer Hallmarks, and GSCA, were used to analyse expression, survival, genomic alterations, protein interactions, pathway enrichment, and drug sensitivity.</div></div><div><h3>Results</h3><div>G6PD is significantly upregulated in HNSCC, correlating with poor overall and disease-free survival. Genomic alterations predominantly involve amplification, while regulatory mutations in NFE2L2 and KEAP1 increase expression, and mutations in HRAS and TACC2 reduce it. Protein interaction analysis links G6PD to oxidative stress, tumour metabolism, and cell migration, with key interactions involving NFE2L2 and HRAS. Enrichment analysis associates G6PD with metastasis, immune evasion, and metabolic reprogramming. Drug sensitivity analysis reveals a complex relationship between G6PD expression and therapeutic response.</div></div><div><h3>Conclusion</h3><div>G6PD is critical in HNSCC progression and may serve as a prognostic biomarker and therapeutic target. Further experimental validation is required to explore G6PD inhibition as a treatment strategy, highlighting the importance of metabolic reprogramming in cancer therapy.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100726"},"PeriodicalIF":0.0,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143474822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-translational regulation of stemness under DNA damage response contributes to the gingivobuccal oral squamous cell carcinoma relapse and progression","authors":"Sachendra Kumar ,&nbsp;Annapoorni Rangarajan ,&nbsp;Debnath Pal","doi":"10.1016/j.oor.2025.100730","DOIUrl":"10.1016/j.oor.2025.100730","url":null,"abstract":"<div><div>Tobacco consumption (smoking and specifically smokeless form) in India contributes to a high prevalence of gingivobuccal oral squamous cell carcinoma (OSCC-GB). OSCC-GB exhibits high rates of locoregional relapse and therapeutic resistance, often attributed to the involvement of cancer stem cells (CSCs). The goal of this study is to leverage the generalizability of the machine learning prediction model for ‘Tumor Status’ for a comparative somatic mutation analysis between ‘With Tumor’ (recurred/relapsed/progressed) and ‘Tumor Free’ (disease-free/complete remission) OSCC-GB patients. Our results showed that support vector machines (SVM) classified the ‘Tumor Status’ classes at a mean accuracy of 89% based on clinical features. Furthermore, RNA-seq based somatic mutation analysis using the classified groups revealed molecular mechanisms underlying tumor progression and remission within OSCC-GB subgroups. The identified mutational signature (C&gt;T mutations) related to DNA damage indicates the influence of tobacco-related carcinogens in OSCC-GB subgroups. The analysis of distinct somatic variants, functional impact predictions, protein-protein interactions, and survival analysis highlights the involvement of DNA damage response (DDR)-related genes in ‘With Tumor’, with particular focus on the significant role of the Mitogen-activated protein kinase associated protein 1 (MAPKAP1) gene, a key player in the mTORC2 signaling pathway. The study indicates that loss-of-function in the identified MAPKAP1 somatic variant may promote stemness and elevated risk of relapse and disease progression in OSCC-GB under conditions of DDR in ‘With Tumor’ OSCC-GB, potentially contributing to increased mortality rates among Indian OSCC-GB patients.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100730"},"PeriodicalIF":0.0,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143480108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a prediction model for risk stratification and outcome prediction in oral oncology patients","authors":"Vishnu Priya Veeraraghavan ,&nbsp;Shikhar Daniel ,&nbsp;Ravikanth Manyam ,&nbsp;Amarender Reddy ,&nbsp;Santosh R. Patil","doi":"10.1016/j.oor.2025.100728","DOIUrl":"10.1016/j.oor.2025.100728","url":null,"abstract":"<div><h3>Background</h3><div>Oral squamous cell carcinoma (OSCC) is a prevalent malignancy with significant morbidity and mortality, particularly in low- and middle-income countries. Despite advancements in treatment, prognostic tools integrating clinical, histopathological, and molecular data remain underdeveloped, limiting personalized risk stratification and survival prediction.</div></div><div><h3>Objective</h3><div>This study aimed to develop and validate a prediction model for overall survival (OS) and progression-free survival (PFS) in OSCC, incorporating clinical, histopathological, and molecular factors.</div></div><div><h3>Methods</h3><div>A retrospective cohort of 132 patients with histopathologically confirmed OSCC was analyzed. Data on demographic, clinical (tumor stage, lymph node involvement), histopathological (tumor grade, perineural invasion), and molecular (HPV status) variables were collected. Logistic regression and machine learning algorithms were used to build the prediction model. Internal validation was conducted using bootstrapping, and model performance was assessed using the area under the receiver operating characteristic (ROC) curve, calibration plots, and decision curve analysis (DCA).</div></div><div><h3>Results</h3><div>The model demonstrated robust predictive performance, with an area under the ROC curve (AUC) of <strong>0.85</strong> for OS and <strong>0.83</strong> for PFS. Tumor stage, lymph node involvement, and HPV status were identified as key predictors of survival. Kaplan-Meier analysis showed steep declines in OS probabilities during the first 24 months, emphasizing the need for early interventions. Calibration plots indicated strong agreement between predicted and observed outcomes, supporting the model's reliability.</div></div><div><h3>Conclusion</h3><div>This study developed a validated prediction model for OS and PFS in OSCC, demonstrating high discriminatory ability and calibration. Integrating clinical, histopathological, and molecular data enhances personalized risk stratification and treatment planning in oral oncology.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100728"},"PeriodicalIF":0.0,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143430173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic variants in immune mediators as potential molecular biomarkers for oral cancer evaluation: Insights from a systematic revaluation by computational analyses and Bayesian approaches","authors":"Juliana Campos Botelho ,&nbsp;Samuel Arcebispo Brasileiro ,&nbsp;André Victor Oliveira Monteiro ,&nbsp;Alessandro Luiz Araújo Bentes Leal ,&nbsp;Naum Neves da Costa dos Santos ,&nbsp;Gabrielly Ribeiro Alves ,&nbsp;Reyce Santos Koga ,&nbsp;Haline Alves da Silva ,&nbsp;José Rogério Souza Monteiro ,&nbsp;Denis Vieira Gomes Ferreira ,&nbsp;Adenilson Leão Pereira ,&nbsp;Ana Carolina Alves de Oliveira ,&nbsp;Márcia Socorro Silva Lima Duarte ,&nbsp;Felipe Rodolfo Pereira da Silva","doi":"10.1016/j.oor.2025.100729","DOIUrl":"10.1016/j.oor.2025.100729","url":null,"abstract":"<div><h3>Background</h3><div>Oral cancer is a complex disease in which genetic variations in immune mediator play a relevant role in its pathophysiology. This study aimed at assessing the level of false-positive rates on meta-analytic data on genetic variations in immune mediator genes related with oral cancer risk.</div></div><div><h3>Material and methods</h3><div>A systematic search was performed for meta-analyses in this field that were published before September 22, 2024. The calculations for the False-Positive Rate Probability (FPRP) and the Bayesian False Discovery Probability (BFDP) were performed to assess the noteworthiness with a statistical power of 1.2 and 1.5 of Odds Ratio (OR) at a prior probability of 10⁻³ and 10⁻⁶. A methodological evaluation by the Venice criteria was performed and <em>in silico</em> networks were designed.</div></div><div><h3>Results</h3><div>Ten meta-analyses on the <em>TNFA</em>/rs361625/rs1800629, <em>VEGF</em>/rs3025039, <em>IL4</em>/rs2070874, <em>IL6</em>/rs1800795, <em>IL8</em>/rs4073 and <em>IL10</em>/rs1800896 genes/polymorphisms and oral cancer have been included. 88 significant OR association values from the meta-analyses included allowed the performance of 336 calculations for FPRP and 176 for BFDP. We found 35 noteworthy values (10.42 %) for FPRP and 59 noteworthy values (33.52 %) for BFDP that demonstrated the variants in <em>VEGF</em> and <em>IL10</em> with noteworthiness association with oral cancer. The gene-gene and protein-protein networks evidenced the role of <em>VEGF, TNFA, IL4, IL6, IL8</em> and <em>IL10</em> genes in the physiopathology of the disease.</div></div><div><h3>Conclusions</h3><div>The Bayesian calculations and the <em>in-silico</em> analyses indicated the rs3025039 and rs1800896 polymorphisms in the <em>VEGF</em> and <em>IL10</em> genes, respectively, as noteworthy molecular biomarkers for oral cancer risk evaluation.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100729"},"PeriodicalIF":0.0,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143436463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilization of ChatGPT as a reliable aide for differential diagnosis of histopathology in head and neck surgery","authors":"Sayyed Ourmazd Mohseni ,&nbsp;Asal Saeid ,&nbsp;Patrick Wong ,&nbsp;Timothy Neal ,&nbsp;Thomas Schlieve","doi":"10.1016/j.oor.2025.100727","DOIUrl":"10.1016/j.oor.2025.100727","url":null,"abstract":"<div><h3>Objectives</h3><div>The rise of artificial intelligence offers promising advancements in diagnostic workflows in healthcare. In oral and maxillofacial surgery, timely and accurate histopathological diagnosis is crucial for effective treatment planning. This study examines Chat Generative Pretrained Transformer (ChatGPT, OpenAI Inc., California) as an aid to providers in generating differential diagnoses for four common maxillofacial pathologies: ameloblastoma, squamous cell carcinoma, mucoepidermoid carcinoma, and pleomorphic adenoma.</div></div><div><h3>Study design</h3><div>A retrospective study was conducted with 200 de-identified histopathological cases, evenly divided across the four diagnostic categories. Each case included clinical summaries and histopathological images, which were input into ChatGPT to generate four differential diagnoses. The study evaluated the inclusion and ranking of the correct diagnosis in the differential list using a chi-square goodness-of-fit test.</div></div><div><h3>Results</h3><div>ChatGPT included the correct diagnosis in all cases (100 %), ranking it first in 49.5 %, second in 32.5 %, third in 14.5 %, and fourth in 3.5 %. Statistical analysis confirmed a significant preference for higher ranking of correct diagnoses (p &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>ChatGPT shows strong reliability in generating accurate differential diagnoses for maxillofacial histopathology, ranking the correct diagnosis in the top two positions in 82 % of cases. These results highlight AI's potential to augment diagnostic workflows and enhance efficiency.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100727"},"PeriodicalIF":0.0,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143430172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Otolaryngology practitioner attitudes toward human papillomavirus vaccination in academic otolaryngology clinics","authors":"Dante J. Merlino ,&nbsp;Katelyn S. Rourk ,&nbsp;George B. Sankar ,&nbsp;Adam J. Luginbuhl ,&nbsp;Brian J. Boyce ,&nbsp;Michelle M. Chen ,&nbsp;Eric M. Dowling ,&nbsp;Michael C. Topf ,&nbsp;Raymond L. Chai ,&nbsp;Karthik Rajasekaran ,&nbsp;Eric J. Moore ,&nbsp;Daniel L. Price ,&nbsp;George Saieed ,&nbsp;Kathryn M. Van Abel","doi":"10.1016/j.oor.2025.100722","DOIUrl":"10.1016/j.oor.2025.100722","url":null,"abstract":"<div><div>Despite the existence of a highly effective and safe vaccine against human papillomavirus (HPV) infection, vaccination rates remain low. The most prevalent HPV-associated malignancy in the United States is oropharyngeal cancer, but otolaryngology practitioners do not offer the HPV vaccine, and their feelings around offering HPV vaccination have not been evaluated. A 43-question survey, including a twelve-question knowledge quiz, was sent to otolaryngology practitioners at seven academic institutions. Twelve questions comprised a knowledge quiz testing practitioner understanding of HPV, while the remainder of the questions evaluated comfort with and likelihood of recommending vaccination. Of the 442 practitioners who were sent the survey, 207 (47 %) completed it, including 27 (13 %) advanced practice providers (physician assistants, nurse practitioners, or speech language pathologists), 89 (43 %) residents or fellows, and 91 (44 %) attending physicians. Together, 181/207 (87 %) of providers were “relatively likely” (n = 54, 26 %) or “extremely likely” (n = 127, 61 %) to offer vaccination. Likelihood of offering the vaccine was associated with multiple measures of provider confidence regarding HPV vaccination discussions, and was not associated with provider type, attending physician subspecialty, or knowledge quiz accuracy (p = 0.11, p = 0.35, and p = 0.67, respectively). In summary, this study suggests a possible new avenue for point-of-care vaccines against HPV. Efforts to improve otolaryngology provider confidence with this recommendation are needed.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100722"},"PeriodicalIF":0.0,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143421123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}